Essential Premium

Tiger Cubs Cash In as Stripe’s Valuation Takes Off

A major secondary sale delivers fresh gains to early hedge fund backers.

Biotech Rebound Boosts Doris Duke’s Mission-Aligned Portfolio

Life sciences is just one part of the foundation’s impact investment strategy, but the sector’s resurgence helped contribute to strong gains in 2025.

Sponsored

Asia’s Growing Economic Power Shapes Global Derivatives Market

Caxton’s U.S. Stock Book Jumps 40 Percent as Law Adds Three New Mega Positions

Andrew Law reshaped the macro fund’s equity portfolio in the fourth quarter, with Tesla expanding and new bets on AMD, BP, and Barrick immediately landing in the top tier of holdings.

Related Content

You’re Doing It Wrong: A Tail-Risk Hedger Calls Out His Industry

Julie Segal

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram